183 reports of this reaction
2.4% of all DEXMETHYLPHENIDATE HYDROCHLORIDE reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for DEXMETHYLPHENIDATE HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 183 FDA adverse event reports linking DEXMETHYLPHENIDATE HYDROCHLORIDE to HEADACHE. This represents approximately 2.4% of all 7,728 adverse event reports for this drug.
Patients taking DEXMETHYLPHENIDATE HYDROCHLORIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for DEXMETHYLPHENIDATE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for DEXMETHYLPHENIDATE HYDROCHLORIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 183 FDA reports for DEXMETHYLPHENIDATE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.4% of all adverse event reports for DEXMETHYLPHENIDATE HYDROCHLORIDE, making it a notable side effect.
If you experience headache while taking DEXMETHYLPHENIDATE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.